March 9, 2021
Business News

Celyad Oncology Establishes At-the-Market Facility

MONT-SAINT-GUIBERT, Belgium–()–Regulatory News:

Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has entered into an Open Market Sale AgreementSM with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, for a period of up to 36 months, through “an at the market offering” (“ATM”), with Jefferies acting as sales agent, up to $25,000,000 of new American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company, assuming sales of…

Click here to view the original article.

Related Posts

You might also like ...

Scoro Raises $16 Million in Series B Funding To Invest In Its End-to-End Work Management Software
Williams Industrial Services Group Announces Election of Robert Mills as Chairman
AON Splash Image
Samenvatting: De NAGA Group AG sluit een financieringskader van USD 30 miljoen af en rapporteert een recordgroei